Going nowhere whilst that gets worked |
I used to be in this a while back and I feel like the time is right to jump back in before it flies. |
Well done! Looks like you got a bargain. This year could be the year the company comes good. |
Hi, what's the evidence for them being buys? |
Looking good |
The bigger sells are actually buys |
Start of the uptrend |
Back in auction
0.07 - 0.07 |
In auction still |
Remember 2 or 3 years ago, the ballpark sum quoted for global sales deal for NPX002 based on $1bn sales per annum was $360- $450 m
So for NPX004 potentially $10bn sales per year by 2028 , well do the math on the potential deal using NPX002 numbers
Mkt cap £0.7m
Page 29 valuation
Bottom paragraph
global sales deal $360 - 450m |
Let’s just be straight …
$10bn sales by 2028 for their lynparza
little old NFX NPX004 out performs Lynparza
current mkt cap just £700k
Make no bones about it ..
AZ will not let NPX004 go anywhere else |
 NPX004 - blockbuster potential
The Group discovered novel forms of olaparib, a drug currently marketed by AstraZeneca, as Lynparza®. Lynparza® was first approved in December 2014 for the treatment of adults with advanced ovarian cancer and deleterious or suspected deleterious germline BRCA mutation. Since then, it has secured similar approvals in breast, pancreatic and prostate cancers with further trials on-going.
These approvals have propelled Lynparza® sales to US$2.6bn in 2022 with industry analysts forecasting annual sales of US$9.7bn by 2028.
Subsequently, further preformulation and in-vitro studies allowed Nuformix to identify lead cocrystals to be progressed for further development.
Results from in vitro dissolution studies demonstrated that the two lead NXP004 cocrystals OUT PERFORMED Lynparza®, both in terms of rate and extent of dissolution and release of olaparib.
Enhancement of dissolution in the currently marketed formulation of Lynparza® resulted in improved bioavailability versus the initial marketed product.
Therefore, NXP004 may offer potential to further increase olaparib's bioavailability. In addition, the potential simplicity of NXP004-based formulations may offer improvements in product cost-of-goods versus the currently marketed product, which requires complex manufacturing methods.
These attributes position NXP004 for applications in line-extensions for the currently marketed product, or for possible development in future first-to-generic product opportunities.This work will direct and support future out-licensing discussions for NXP004.
The Company's NXP004 programme is focused on the development of novel, proprietary, cocrystal forms of olaparib, a drug currently marketed by AstraZeneca, under the Lynparza® brand name.
On 14 June 2024 the US Patent and Trademark Office ("PTO") has granted the Company patent number 12012386 covering the lead cocrystals under development, representing the first granted patent in this second NXP004 cocrystal series.
Dr Dan Gooding, Executive Director of Nuformix, said: "I'm delighted we've received these multiple grants of key patents underpinning both our NXP002 and NXP004 programmes. The European patent grant represents the last major territory to confirm protection of the novel drug forms enabling NXP002's development as a potential novel IPF treatment. Granting of the method of use patent in the US further strengthens our IP position for this programme. The US PTO's decision to grant the patent protecting the NXP004 programme's lead cocrystals is also a first, with other territories soon to follow. The granting of these patents is very helpful and timely in progressing on-going discussions with potential development partners."
June 2024
Dr Dan Gooding, Executive Director of Nuformix, said: "Our research efforts and external discussions to date demonstrate that inhaled treatment of IPF and related fibrotic lung diseases via NXP002 is a viable and attractive concept. We remain focused on generating data and initiating, and further developing, discussions with potential partners that will support our efforts to secure out-license deals on NXP002 and NXP004. Progression of these opportunities is being achieved using existing funds thanks to a lean operational model, which will continue to operate until our R&D and targeted partnering activities require further resource. I am excited by our prospects for the remainder of the year and look forward to sharing results as they emerge."
Mkt cap 700k
IPO £12m
NPX004 potential blockbuster annual sales
Expect more patents in the short term
Commercial discussions with multiple potential partners |
My wife's exactly the same! |
She’s trying to break out |
These commercial discussions with numerous parties , hopeful a deal can be agreed with one
I haven’t checked in here for some time
Are the deal values , still as their presentation from few years ago ?
Slide 16
£61.5m upfront
Mkt cap under £1m
Nice bit of upside if they can get a deal done |
Are we beginning to get a few crumbs of TRLS's glory?? Biotech back in the limelight perhaps! |
At least in a bigger market, take you a month to lose that much. Better value Socio 😂
A big buyer no doubt. Big hit |
Nice experience for Socio. Not even get an invoice for it |
We need a ceo who knows how manage timescales . |
My opinion
He’s tried a deal without ODD
It’s failed !
Absolutely no excuse for such a delay in applying for it. |
Socio, really believe these guys hold 6p? LOLOL |
Thats better P. Lets see if the gerbils can take it out for us now, or minced and we will just watch |
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Hot Features
Premium
